Observational Study on How Zuranolone Helps Reduce Postpartum Depression Symptoms in Adults Using CVS Specialty Pharmacy

What this Trial Is About

This research aims to learn more about how zuranolone affects postpartum depression PPD symptoms in adults who took the medication within one year after the end of their pregnancy. PPD can cause tiredness, sadness, and loss of interest in daily activities. The study is observational, collecting health information from participants who have already been prescribed zuranolone through CVS Specialty Pharmacy in the United States between June 2025 and May 2026. Participants will be contacted by email or phone after filling their zuranolone prescription to ask if they wish to join the study. Those who agree will complete questionnaires about their symptoms using the Edinburgh Postnatal Depression Scale EPDS and answer other surveys about their health and environment. Participants must take their first dose of zuranolone within seven days of joining. The study will follow them by collecting EPDS scores at baseline, Day 15, and Day 45, which is 30 days after treatment ends. Throughout the study, researchers will monitor changes in PPD symptoms using EPDS scores and assess breastfeeding status during treatment. They will also gather information about medication use before, during, and after zuranolone treatment. Participants will complete surveys independently, and the study focuses on understanding how zuranolone influences PPD symptoms over the 45-day period.

A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy